PT - JOURNAL ARTICLE AU - Didzis Gavars AU - Mikus Gavars AU - Dmitry Perminov AU - Janis Stasulans AU - Justine Stana AU - Zane Metla AU - Jana Pavare AU - Eriks Tauckels AU - Egils Gulbis AU - Uga Dumpis TI - Saliva as a testing sample for SARS-CoV-2 detection by RT-PCR in low prevalence community settings AID - 10.1101/2020.10.20.20216127 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.20.20216127 4099 - http://medrxiv.org/content/early/2020/11/30/2020.10.20.20216127.short 4100 - http://medrxiv.org/content/early/2020/11/30/2020.10.20.20216127.full AB - Objectives The number of COVID-19 cases is increasing globally and there is an urgency for a simple non-invasive method for the detection of SARS-CoV-2. Our study aimed to demonstrate that saliva can be used as a specimen for SARS-CoV-2 detection notably for the screening of extensive population groups via pooling.Methods To demonstrate that saliva is an appropriate specimen for SARS-CoV-2 detection a field study including 3,660 participants was performed between September 29 and October 1, 2020. We collected paired nasopharyngeal/oropharyngeal swabs (NPS) and saliva specimens and processed them within 24 hours of collection. We performed 36 serial measurements of 8 SARS-CoV-2 positive saliva samples to confirm the stability of the specimen and completed 37 pools of saliva samples by adding one positive specimen per pool.Results Saliva specimens were stable for testing for up to 24 hours. Overall, 44 salival samples (1.2%) tested positive for SARS-CoV-2 during the field study. The results of saliva samples were consistent with those obtained from NPS from the same patient with 90% sensitivity (95% CI 68.3%-98.7%) and 100% specificity during the first two weeks after the onset of symptoms. Using pooling strategy 796 RT-PCR tests were performed. All pools showed 100% positivity in different pooling proportions.Conclusions Our findings demonstrate that saliva is an appropriate specimen for pooling and SARS-CoV-2 screening with accurate diagnostic performance. Patient-performed simple specimen collection allows testing an extensive number of people rapidly, obtaining results of the spread of SARS-CoV-2 and allowing authorities to take timely measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMinistry of Education and Science, Republic of Latvia. Funding number: VPP-COVID-2020/1-0008. Additional funding was provided by E.Gulbja laboratory.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Ethics Committee of Pauls Stradins Clinical university hospital (record No 300720-18L).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this published article.